Phacilitate Leaders World

Sponsors & Exhibitors

Sponsors & Exhibitors

Loading
  • Letter
    • D
  • Daewoong Group is a global healthcare group established in 1945 under the vision to ‘manufacture high quality pharmaceuticals to enhance people’s health and create a healthy society’. As it is our vis ...
  • At Dark Horse Consulting, we specialize in the development of Cell and Gene Therapy products. All of our consultants have deep Cell and Gene Therapy industry experience, spanning diverse functions inc ...
  • Delphi Genetics

    Stand: 1
    Delphi Genetics is a private biotech company located in the Biopark of Gosselies, Belgium, with proven track record in genetic engineering and bioproduction.  The company provides one-stop-shop servic ...
  • Dynamic Star

    Stand: 601e
    The Life Science Center at Fordham Landing: A Dynamic Star Development New York’s regenerative medicine epicenter - will provide offices, wet labs, and cGMP facilities specifically designed for cuttin ...
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK